C2S-Scale: a model-generated cancer hypothesis confirmed in cells
The 27-billion-parameter single-cell model, built on Gemma with Yale, predicted that silmitasertib would increase antigen presentation only in an immune-positive context. In human neuroendocrine cell models with low-dose interferon, the increase was about 50%. Validation is in cells only; the authors call this ‘a first step.’
Technology: C2S-Scale 27B (Gemma)
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: The model's prediction that silmitasertib boosts antigen presentation with low-dose interferon was tested experimentally in human neuroendocrine cell models not seen in training, with a roughly 50% synergistic increase reported.
- Still unknown: The article calls this an early first step, validation is in cell models only, and clinical use is not shown.
- AI role: The 27B single-cell language model C2S-Scale ran a dual-context virtual screen of over 4,000 drugs and generated the hypothesis.
Evidence sources: https://blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery/ · https://www.biorxiv.org/content/10.1101/2025.04.14.648850
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: blog. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.